Sharps Technology, Inc. STSS stock is trading higher on Wednesday.As per data from Benzinga Pro, session volume stands at 31.74 million versus an average volume of 674.72k.What Happened: The medical device and pharmaceutical packaging company initiated shipments for previously announced purchase orders across three customer orders.These shipments mark the company’s first deliveries of its SecureGard and SoloGard product lines and its transition to generating commercial revenue.“These initial shipments mark ...

Summary of Sharps Technology (STSS) Conference Call - May 22, 2025 Company Overview - **Company**: Sharps Technology (STSS) - **Industry**: Medical Devices, specifically focusing on syringe technology Key Points and Arguments 1. **Sales Agreement**: The company executed a $50,000,000 sales agreement with a large US filler for 10 ml syringes, signed in July 2024, which will utilize most of the capacity of their European facility [1][2] 2. **Expansion Potential**: The agreement has the potential to expand production by an additional 250 million units, supported by a financial raise with Aegis to enhance equipment and technology [2] 3. **Facility Details**: The European facility is debt-free and specializes in smart safety syringe technology, with plans for scalability and expansion to meet contract demands [2][3] 4. **US Manufacturing Facility**: The company is actively seeking a US manufacturing facility, particularly in South Carolina, to produce prefillable syringes using advanced copolymer technology, which is seen as a significant growth area in drug delivery [3][4] 5. **Product Overview**: Current products include SecurGuard and Solarguard syringes, which feature low waste technology and passive safety mechanisms [4][5] 6. **Market Growth**: The prefilled syringe market is rapidly growing, with significant investments from healthcare companies, indicating a strong opportunity for organic growth and partnerships [8][9] 7. **Regulatory Challenges**: The medical device industry has a lengthy lifecycle from concept to commercialization, requiring extensive regulatory approvals [14][15] 8. **Revenue Generation**: The company anticipates early revenue generation in Q2 2025 from initial shipments to the US customer, with a commitment for ongoing orders as production scales [7][28] 9. **Debt Status**: The company is currently debt-free after using part of a $20,000,000 financing to pay down previous loans [25] 10. **Future Projections**: Plans to be cash flow positive by next year, with strategic projects aimed at bringing prefillable syringes to market [35] Additional Important Information 1. **Reverse Stock Split**: A reverse stock split was executed to comply with Nasdaq requirements, which is expected to enhance long-term value for investors [21][31] 2. **Warrant Structure**: Most warrants have been eliminated, improving the company's financial position [33] 3. **Market Demand**: There is increasing demand for prefilled syringes, with copolymer technology offering advantages over traditional glass syringes, such as reduced breakage and improved manufacturing processes [40][42] 4. **Production Capabilities**: The Hungarian facility is positioned to support both current and future production demands, with potential for expansion and flexibility in product offerings [50][52] This summary encapsulates the key insights from the conference call, highlighting Sharps Technology's strategic initiatives, market opportunities, and operational capabilities within the medical device industry.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces that it has received a notice from Nasdaq confirming that the Company has regained compliance with The Nasdaq's Capital Market's minimum bid price requirement of $1.00 per share and the minimum stockholders’ equity requirement of $2.5 mi ...

Company Overview - Sharps Technology, Inc. is an innovative medical device and pharmaceutical packaging company that offers patented, best-in-class smart-safety syringe products to the healthcare industry [2] - The company's product lines focus on ultra-low waste capabilities and incorporate both passive and active safety features in syringe technologies [2] - Sharps Technology also provides products designed with specialized copolymer technology to support the prefillable syringe market segment [2] - The company operates a manufacturing facility located in Hungary [2] Presentation Details - Robert Hayes, the CEO of Sharps Technology, is scheduled to present at the Aegis Capital Corp. 2025 Virtual Conference on May 22, 2025, at 1:00 p.m. ET [1][4] - The presentation will be webcasted, allowing broader access to stakeholders and interested parties [1][4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) of incorporation or organization Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (I.R.S. Employer Identification No.) 105 Maxess Road, Melville, ...

Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry ...

Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreementInvestments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products ...

Core Points - Sharps Technology, Inc. will implement a 1-for-300 reverse stock split effective April 27, 2025, to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse split will reduce the authorized common shares from 500,000,000 to 1,666,667, and it was approved by the Board without shareholder consent [3] Company Overview - Sharps Technology is a medical device and pharmaceutical packaging company that specializes in patented smart-safety syringe products aimed at the healthcare industry [4] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [4] - Sharps also produces products designed with specialized copolymer technology for the prefillable syringe market segment and operates a manufacturing facility in Hungary [4]

Financial Performance - The company incurred net losses of $9,296,202 and $9,841,638 for the years ended December 31, 2024 and 2023, respectively[129]. - The company has not generated any revenue to date[170]. - Annual revenue for the most recently completed fiscal year was less than $100 million, allowing the company to maintain its smaller reporting company status[183]. Revenue Generation and Offerings - The company generated no revenue since its inception in 2017 until the fourth quarter of 2022, when it began building inventory of syringe products[129]. - The company raised approximately $20.0 million in gross proceeds from the 2025 Offering, with net proceeds of approximately $18.2 million after expenses[133]. - The 2025 Offering included 14,285,714 units, generating gross proceeds of $12.6 million from Common Units and $7.4 million from Pre-Funded Units[134]. - The company completed an Initial Public Offering on April 19, 2022, raising net proceeds of approximately $14.2 million[132]. - The company entered into a securities purchase agreement on September 20, 2024, for an aggregate principal amount of $4,375,000, resulting in gross proceeds of approximately $3.5 million[138]. Expenses and Financial Position - The company has incurred significant research and development expenses, primarily related to its syringe products, and expects these expenses to increase in the foreseeable future[131]. - Research and Development (R&D) expenses increased to $2,471,762 in 2024 from $1,605,547 in 2023, representing a 54% increase[171]. - General and Administrative (G&A) expenses decreased to $7,154,948 in 2024 from $8,521,103 in 2023, a reduction of 16%[172]. - Net interest expense changed from income of $138,118 in 2023 to an expense of $1,664,712 in 2024, a change of 1,305%[173]. - Cash balance decreased to $864,041 in 2024 from $3,012,908 in 2023, indicating a significant reduction in liquidity[176]. - Working capital deficit increased to $2,011,678 in 2024 from a working capital of $1,145,569 in 2023[176]. - Net cash used in operating activities was $6,929,545 in 2024, down from $8,507,300 in 2023[178]. - Net cash used in investing activities increased to $1,163,137 in 2024 from $698,277 in 2023[179]. - Net cash provided by financing activities decreased to $5,907,407 in 2024 from $8,029,628 in 2023[180]. Compliance and Regulatory Status - The company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, and is awaiting a hearing date for its appeal[141]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to take advantage of various reporting exemptions[181]. - The company will cease to be an emerging growth company if annual gross revenue exceeds $1.07 billion or if the market value of common stock held by non-affiliates exceeds $700 million[182]. - The company is also a "smaller reporting company," with a market value of stock held by non-affiliates and gross proceeds from the IPO being less than $700 million[183]. - As a smaller reporting company, the company may present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K[183]. - The company intends to utilize exemptions from certain disclosure requirements available to both emerging growth and smaller reporting companies[183]. - The company has not issued more than $1.0 billion in non-convertible debt securities in the previous three-year period[182]. - The company may face a less active trading market for its common shares if investors find the reduced disclosures less attractive[182]. - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[184]. Distribution Agreement - The company has a distribution agreement that was mutually terminated on February 5, 2025, with no economic benefit obtained from it[140].

Core Viewpoint - The company emphasizes the importance of shareholders voting 'FOR' the proposed reverse stock split to maintain its Nasdaq listing and avoid delisting to the OTC Markets [1][4][6]. Group 1: Importance of Voting - A positive shareholder vote is crucial for Sharps Technology to comply with Nasdaq's minimum bid price requirement of $1.00 per share [7]. - The company has scheduled a special shareholder meeting on March 28, 2025, urging shareholders to submit their proxy votes beforehand [5]. - The Board of Directors unanimously supports the reverse stock split proposal and encourages all shareholders to vote in favor [5][6]. Group 2: Consequences of Delisting - Failure to approve the reverse stock split could lead to delisting from Nasdaq, resulting in trading on the OTC Markets, which may significantly reduce liquidity [2][4]. - Delisting could adversely affect the value of the company's securities and complicate trading volume, making it harder for investors to buy and sell shares [6][8]. - Maintaining a Nasdaq listing is essential for sustaining interest from analysts and brokers, which is vital for the company's growth initiatives [6][8]. Group 3: Reverse Stock Split Process - If approved, the reverse stock split will reduce the number of outstanding shares while maintaining the same percentage interest for shareholders [7]. - This mechanism is often used by companies to regain compliance with exchange listing requirements [7]. - The company has filed a Definitive Proxy Statement with the SEC regarding the reverse stock split proposal [8]. Group 4: Company Overview - Sharps Technology is a medical device and pharmaceutical packaging company specializing in patented syringe products with safety features [9]. - The company focuses on ultra-low waste capabilities and has a manufacturing facility in Hungary [9].